Hey There Income Hunters,
Cannabis is one of the most exciting investments in the world.
And I mean that sincerely — I'm not a weed dealer!
See, the real value of cannabis has little to do with marijuana, rather it’s all about hemp fiber, which has an array of uses from rope to paper to clothing and, of course, hemp oil…
Heck, Henry Ford rolled up, er, rolled out a car made largely from hemp …
Want more? George Washington was a hemp farmer. And hemp was used in the sails and lines of the Mayflower. (Plymouth Rock? More like Plymouth rocks!)
However, like any innovative, valuable and unique find that is not initially under tight government control, cannabis eventually became heavily regulated. (Sounds a little like what crypto is going through now.)
The Marihuana Tax Act of 1937 (actual spelling!) taxed cannabis sales. And in the 1980s, marijuana was labeled as a Schedule I drug alongside heroin and LSD under the Controlled Substances Act.
How is marijuana listed as more dangerous than crystal meth and cocaine …
Today, the pendulum has swung as politicians push for any tax revenue and new jobs they can find, among other reasons.
#IncomeHunters need to start now building a portfolio of stocks that are positioned to profit from an explosion of interest in the industry, as full decriminalization and descheduling are expected by year's end.
Potential Cannabinoid Health Benefits
CBD is currently a $ 1billion dollar industry and is expected to explode and grow at a compound annual growth rate (CAGR) of 40.4% for the period of 2020-2025.
Some projections have the global medical cannabis market size rising to $44.5 billion by 2025.
Reasons to Believe the Market Will be Much Larger
- Many potential users live in states where cannabis is still illegal and won’t even consider using due to massive fines and potential imprisonment. With greater legalization, expect more first-time users.
- As the product becomes readily available and is infused into beverages, edibles and oils, the market will open up to a whole new market of non-smoking consumers.
- Expect explosive growth as the product offers an alternative to Big Pharma’s deadly narcotic painkillers. Cheaper, non-lethal pain relief is a monster growth driver on its own.
Institutional Buyers Have Yet to Arrive
It is to investors' benefit that, to date, there has been little brand awareness.
This industry has yet to bloom, as it were.
We will see a rush of corporate interest and activity in the leading cannabis stocks the day Washington reveals its intentions to review Cannabis as a Schedule I drug.
This is a rare opportunity for retail investors to have a headstart in an industry that will no doubt flourish, pending regulatory approval …
This week, I will provide a comprehensive summary on my top-three cannabis companies based on quality of management, expanse of network, insider ownership and share structure to “weed” out potential dilution, which is always a risk in a start-up industry.
Bring It Home
I’ll say it: I am so thrilled to be around to see pot have its day in the sun.
The bad rap it’s gotten over the years has been incredible.
I was a teenager in the 1970s and it was just part of our culture at the time. I seem to recall declaring that it was a miracle drug …
Now I might actually hear a medical professional declare that exact sentiment.
Standby for the company summaries I have coming your way this week.
Until then …
Live and Trade With Passion My Friends,